Sell AstraZeneca, says UBS, which upgrades European rivals including GSK

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.

Related Keywords

China ,London ,City Of ,United Kingdom ,Denmark ,Danish ,Novo Nordisk ,Matthew Weston ,Astrazeneca ,Novartis ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Healthcare Life Sciences ,Aerospace Defense ,Biopharmaceuticals ,Defense Equipment Products ,Industrial Goods ,Corporate Strategy Planning ,Analyst Comment Recommendation ,Corporate Industrial News ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,Astrazeneca Plc ,Uk Azn ,Astrazeneca Plc Adr ,Azn ,Gsk Plc ,Uk Gsk ,Gsk Plc Adr ,Gsk ,Novartis Ag ,Ch Novn ,Novartis Ag Adr ,Nvs ,Sanofi Sa ,Fr San ,Sanofi Adr ,Sny ,Novo Nordiska S ,Dk Novo B ,Corporate Strategy ,Planning ,Analyst Comment ,Recommendation ,Corporate ,Industrial News ,Healthcare ,Life Sciences ,Aerospace ,Defense ,Defense Equipment ,Products ,